Asterias Biotherapeutics, Inc. Company Review & Valuation
About Asterias Biotherapeutics, Inc.
Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer.
Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia.
The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc.
in March 2013.
Asterias Biotherapeutics, Inc.
was founded in 2012 and is headquartered in Fremont, California.